A new version of CAR with improved antigen sensitivity

Xiaolei Su

Assistant Professor of Cell Biology

Yale University

Yale Innovation Summit 2023

Team



Xiaolei Su, PhD
Assistant Professor
Principal Investigator

Xinyan Zhang, MD
Postdoc
Leading scientist

Fawzaan Hashmi
Research Assistant
Scientist



Sidi Chen, PhD
Associate Professor
Collaborator

Iris Isufi, MD
Associate Professor
Collaborator

Challenges

Current CARs have low antigen sensitivity:

- Failure to target low antigen-expressing cancer cells
- Frequent relapse during prolonged treatment of high antigen-expressing cancers because of antigen loss

Solution

Development of IDR CARs with enhanced antigen sensitivity towards blood and solid tumors

Impact

- Expand the target of CAR-T to low antigen-expressing cancers
- Reduce relapse frequency

Innovation

- IDR broadly improves antigen sensitivity of CARs targeting a variety of antigens
- IDR-induced biomolecular condensation promotes CAR-T activity
- IDR CAR can be combined with other strategies to improve CAR-T in an additive or synergistic manner

Data: IDR enhanced the killing of low antigen-expressing cancers





Null Control IDR1 IDR2 IDR3

Usage of the fund

To evaluate the safety of IDR CAR-Ts in mouse models

Milestone

Identification of the IDR that achieves a balance between tumor eradication and tissue toxicity